22.94
-3.06 (-11.77%)
| Previous Close | 26.00 |
| Volume | 40,557,342 |
| Price / Earnings (Forward) | 67.53 |
| Price / Sales | 2.49 |
| Price / Book | 18.72 |
| 52 Weeks Range |
| Profit Margin | 9.21% |
| Operating Margin (TTM) | 10.12% |
| Diluted EPS (TTM) | 0.680 |
| Quarterly Revenue Growth (YOY) | 110.70% |
| Quarterly Earnings Growth (YOY) | 344.70% |
| Total Debt/Equity (MRQ) | 11.54% |
| Current Ratio (MRQ) | 1.59 |
| Operating Cash Flow (TTM) | 334.34 M |
| Levered Free Cash Flow (TTM) | 213.45 M |
| Return on Assets (TTM) | 10.76% |
| Return on Equity (TTM) | 36.79% |
AIStockmoo Score
| Value 30% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | -2.2 |
| Financial Health info | 3.4 |
| Timing 30% | -2.5 |
| AI Technical info | NA |
| Technical Oscillators info | -2.5 |
| Technical Moving Averages info | -2.5 |
| Sentiment 20% | 0.0 |
| Analyst Consensus info | 0.0 |
| News Mood info | NA |
| Smart Money 20% | 0.0 |
| Insider Activity info | 0.0 |
| Institutional Flow info | NA |
| Environment | ×1.15 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -4.0% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | 4.4 |
| Final Score | -0.85 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Hims & Hers Health, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| HIMS | - | - | - | 18.72 |
| RDY | - | 0.68% | - | 3.07 |
| TAK | - | 4.61% | - | 1.43 |
| HLN | - | 2.14% | - | 1.84 |
| TEVA | - | - | - | 6.23 |
| ZTS | - | 2.81% | - | 10.19 |
Select this tab to load the latest available analysis.
|
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 11.13% |
| % Held by Institutions | 82.47% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Aug 2026 | CNBC | Hims & Hers CEO says FTC lawsuit misunderstands how the company works |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |